Luca Schierbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luca Schierbaum has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Darius Ebrahimi-Fakhari
Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publications Aaron Bao
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
1 shared publicationAbdul A. Halawi
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
1 shared publication- Afshin Saffari
Movement Disorders Program, Department of Neurology and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA; Division of Child Neurology and Metabolic Medicine, Centre for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
1 shared publication - Amar J. Majmundar
Division of Nephrology, Boston Children's Hospital, Boston, MA, United States
1 shared publication - Amy Tam
Movement Disorders Program, Department of Neurology & F.M. Kirby Neurobiology Center Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (2) , e200249
The Spastic Paraplegia–Centers of Excellence Research Network (SP-CERN)
The primary objective of this paper was to present the establishment of the Spastic Paraplegia-Centers of Excellence Research Network (SP-CERN) aimed at promoting clinical trial readiness for hereditary spastic paraplegia (HSP). SP-CERN is unique in its approach to addressing the diagnostic and therapeutic challenges associated with HSP through a large-scale, collaborative effort. Participants with HSP are identified through multicenter collaborations across 11 institutions in the United States. SP-CERN systematically collects longitudinal clinical data, biospecimens, and wearable device data from patients. Data are stored in a centralized REDCap database, facilitating shared access for analysis. Patients are evaluated using standardized assessment tools for motor function, biomarkers, and digital outcome measures. SP-CERN has established a biorepository, centralized data collection methods, and standardized clinical assessments. It is conducting natural history studies for all HSP subtypes, enabling the validation of biomarkers and development of gene-based therapies. SP-CERN's collaborative approach bridges gaps in clinical care and research for HSP by improving diagnostic capabilities and promoting clinical trial readiness. This initiative represents a framework for rare disease research, accelerating the development of novel therapies and improving patient outcomes through standardized, multi-institutional collaboration.
- 1 April 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (2) , e200249
Open AccessThe Spastic Paraplegia–Centers of Excellence Research Network (SP-CERN)
The primary objective of this paper was to present the establishment of the Spastic Paraplegia-Centers of Excellence Research Network (SP-CERN) aimed at promoting clinical trial readiness for hereditary spastic paraplegia (HSP). SP-CERN is unique in its approach to addressing the diagnostic and therapeutic challenges associated with HSP through a large-scale, collaborative effort. Participants with HSP are identified through multicenter collaborations across 11 institutions in the United States. SP-CERN systematically collects longitudinal clinical data, biospecimens, and wearable device data from patients. Data are stored in a centralized REDCap database, facilitating shared access for analysis. Patients are evaluated using standardized assessment tools for motor function, biomarkers, and digital outcome measures. SP-CERN has established a biorepository, centralized data collection methods, and standardized clinical assessments. It is conducting natural history studies for all HSP subtypes, enabling the validation of biomarkers and development of gene-based therapies. SP-CERN's collaborative approach bridges gaps in clinical care and research for HSP by improving diagnostic capabilities and promoting clinical trial readiness. This initiative represents a framework for rare disease research, accelerating the development of novel therapies and improving patient outcomes through standardized, multi-institutional collaboration.
- Open Access
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101280
Expanding the spectrum of novel candidate genes using trio exome sequencing and identification of monogenic cause in 27.5% of 320 families with steroid-resistant nephrotic syndrome
- 1 March 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (2) , 101280
Open AccessExpanding the spectrum of novel candidate genes using trio exome sequencing and identification of monogenic cause in 27.5% of 320 families with steroid-resistant nephrotic syndrome
- 24 December 2024
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (3) , 101349
Quantitative natural history modeling of HPDL-related disease based on cross-sectional data reveals genotype-phenotype correlations
- 24 December 2024
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (3) , 101349
Quantitative natural history modeling of HPDL-related disease based on cross-sectional data reveals genotype-phenotype correlations